Enlivex Therapeutics Ltd. (FRA:1BT)

Germany flag Germany · Delayed Price · Currency is EUR
0.920
+0.115 (14.29%)
At close: Dec 4, 2025
-8.91%
Market Cap 24.16M
Revenue (ttm) n/a
Net Income (ttm) -10.83M
Shares Out n/a
EPS (ttm) -0.46
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume n/a
Average Volume 375
Open 0.920
Previous Close 0.805
Day's Range 0.920 - 0.920
52-Week Range 0.750 - 1.710
Beta n/a
RSI 61.28
Earnings Date Nov 28, 2025

About Enlivex Therapeutics

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra (ENX-CL-02-002), which is in phase II clinical trial for the treatment of organ dysfunction and failure caused by sepsis; and Allocetra (ENX-CL-05-001), which is in phase I/II clinical trial to treat moderate knee osteoarthritis. The company also develops 0189-22-KMC, which is in phase I/II clinical trial to treat end-stage knee osteoarthritis; 0006-24-KMC, which ... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2005
Country Israel
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol 1BT
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements

News

There is no news available yet.